Inhibikase Therapeutics Inc
For the period ended Jun 30, 2024. Filed Aug 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 14, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
| Incorporated by Reference to SEC Filing | |||||
|---|---|---|---|---|---|
| ExhibitNo. | Filed Exhibit Description | Form | ExhibitNo. | File No. | Date Filed |
| 3.1 | Amended and Restated Certificate of Incorporation of Inhibikase Therapeutics, Inc., as most recently amended and restated effective Wednesday, December 23, 2020. | 8-K | 3.1 | 001-39676 | 12/29/2020 |
| 3.2 | Certificate of Amendment to Amended and Restated Certificate of Incorporation of Inhibikase Therapeutics, Inc. | 8-K | 3.1 | 001-39676 | 06/29/2023 |
| 3.3 | Amended and Restated Bylaws of Inhibikase Therapeutics, Inc. | 8-K | 3.3 | 001-39676 | 12/29/2020 |
| 4.1 | Form of Pre-Funded Warrant (May 2024) | 8-K | 4.1 | 001-39676 | 05/20/2024 |
| 4.2 | Form of Series A Warrant (May 2024) | 8-K | 4.2 | 001-39676 | 05/20/2024 |
| 4.3 | Form of Series B Warrant (May 2024) | 8-K | 4.3 | 001-39676 | 05/20/2024 |
| 4.4 | Form of Series C Warrant (May 2024) | 8-K | 4.4 | 001-39676 | 05/20/2024 |
| 4.5 | Form of Series D Warrant (May 2024) | 8-K | 4.5 | 001-39676 | 05/20/2024 |
| 4.6 | Form of Warrant Amendment (May 2024) | 8-K | 4.6 | 001-39676 | 05/20/2024 |
| 10.1 | Employment Agreement between Inhibikase Therapeutics, Inc. and Garth Lees-Rolfe, dated as of April 1, 2024 | S-1 | 10.18 | 333-278844 | 04/19/2024 |
| 10.2 | Securities Purchase Agreement, dated as of May 20, 2024 | 8-K | 10.1 | 001-39676 | 05/20/2024 |
| 10.3 | Placement Agency Agreement, dated as of May 20, 2024 | 8-K | 10.2 | 001-39676 | 05/20/2024 |
| 10.4 | Inducement Letter, dated as of May 20, 2024 | 8-K | 10.3 | 001-39676 | 05/20/2024 |
| 31.1* | Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | ||||
| 31.2* | Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | ||||
| 32.1** | Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | ||||
| 32.2** | Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | ||||
| 101.INS | Inline XBRL Instance Document | ||||
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document | ||||
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document | ||||
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document | ||||
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document | ||||
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document | ||||
| 104 | Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101) | ||||
- Filed herewith.
** Furnished herewith.
A contract, compensatory plan or arrangement to which a director or executive officers is a party or in which one or more directors or executive officers are eligible to participate.
Exhibits 32.1 and 32.2 are being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that section, nor shall such exhibits be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act or the Exchange Act, except as otherwise stated in any such filing.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.